Atovaquone

	WikiDoc Resources for Atovaquone
Articles
Most recent articles on Atovaquone Most cited articles on Atovaquone Review articles on Atovaquone Articles on Atovaquone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Atovaquone Images of Atovaquone Photos of Atovaquone Podcasts & MP3s on Atovaquone Videos on Atovaquone
Evidence Based Medicine
Cochrane Collaboration on Atovaquone Bandolier on Atovaquone TRIP on Atovaquone
Clinical Trials
Ongoing Trials on Atovaquone at Clinical Trials.gov Trial results on Atovaquone Clinical Trials on Atovaquone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Atovaquone NICE Guidance on Atovaquone NHS PRODIGY Guidance FDA on Atovaquone CDC on Atovaquone
Books
Books on Atovaquone
News
Atovaquone in the news Be alerted to news on Atovaquone News trends on Atovaquone
Commentary
Blogs on Atovaquone
Definitions
Definitions of Atovaquone
Patient Resources / Community
Patient resources on Atovaquone Discussion groups on Atovaquone Patient Handouts on Atovaquone Directions to Hospitals Treating Atovaquone Risk calculators and risk factors for Atovaquone
Healthcare Provider Resources
Symptoms of Atovaquone Causes & Risk Factors for Atovaquone Diagnostic studies for Atovaquone Treatment of Atovaquone
Continuing Medical Education (CME)
CME Programs on Atovaquone
International
Atovaquone en Espanol Atovaquone en Francais
Business
Atovaquone in the Marketplace Patents on Atovaquone
Experimental / Informatics
List of terms related to Atovaquone

Atovaquone
Clinical data
Routes of; administration	oral only
ATC code	P01AX06 (WHO) ;
Legal status
Legal status	PoM (UK), Rx [US];
Pharmacokinetic data
Elimination half-life	2.2 to 3.2 days
Identifiers
	IUPAC name 3-[4-(4-chlorophenyl)cyclohexyl]- 4-hydroxy-naphthalene-1,2-dione;
CAS Number	95233-18-4;
PubChem CID	74989;
DrugBank	APRD00805;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H19ClO3
Molar mass	366.837 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Malarone anti-malaria tablets, as issued in the UK.

Atovaquone (alternative spelling: atavaquone) is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity. Its average wholesale price is about $2.13 per standard 250 mg. tablet.^[1] It is also manufactured in the US in the liquid form, or oral suspension, under the brand name Mepron.^[2]

Atovaquone is a medication used to treat or prevent:

Pneumocystis pneumonia (PCP), although it is not approved for treatment of severe PCP.
Toxoplasmosis. The medication has antiparasitic and therapeutic effects.
Malaria. It is one of the two components (along with proguanil) in the drug Malarone. Malarone has fewer side effects than mefloquine, but can be more expensive because it's taken daily.^[3]

Trimethoprim-sulfamethoxazole (TMP-SMX, Bactrim) is generally considered first line therapy for PCP or toxoplasmosis. However, atovaquone may be used in patients who cannot tolerate, or are allergic to, TMP-SMX. In addition, atovaquone has the advantage of not causing myelosuppression, which is an important issue in patients who have undergone bone marrow transplantation.

Malaria

Atovaquone is only available as a fixed preparation with proguanil that has been commercially available from GlaxoSmithKline since 2000 as Malarone® (sometimes abbreviated A+P). It can be used both to treat and to prevent malaria.

A "standard" tablet of Malarone contains 100 mg of proguanil hydrochloride and 250 mg of atovaquone. A "pediatric" tablet of Malarone contains 25 mg of proguanil hydrochloride and 62.5 mg of atovaquone.

Treatment

The adult treatment dose is four "standard" tablets once a day for three days. In children, the drug is prescribed by body weight:

11 to 20 kg: 1 "standard" tablet once daily for 3 days;
21 to 30 kg: 2 "standard" tablets once daily for 3 days;
31 to 40 kg: 3 "standard" tablets once daily for 3 days;
41 kg and above: use adult dose.

Malarone is not licensed for use in children weighing 10 kg or less. The "pediatric" tablets are not used in malaria treatment.

The advice of a specialist should always be sought when starting malaria treatment. Malarone should not be used to treat severe malaria, when an injectable drug (quinine or artesunate in the UK; quinidine in the US) should be used instead.

Prevention

Medical advice should always be taken before choosing a drug for malaria prevention. Because some strains of malaria are resistant, Malarone is not effective for malaria prevention in all parts of the world. It must be taken with a fatty meal or at least some milk to be absorbed adequately.

The adult dose is one "standard" tablet daily starting one or two days before traveling into a malaria-endemic area, and continuing throughout the stay and then for another 7 days after returning from the malarious area.

The child dose is prescribed according to body weight:

11–20 kg: 1 "pediatric" tablet once daily;
21–30 kg: 2 "pediatric" tablets once daily;
31–40 kg: 3 "pediatric" tablets once daily;
41 kg and above use adult dose.

The duration of treatment is the same as for adults.

Resistance

Proguanil acts as a mitochondrial sensitiser and synergizes with atovaquone; also, there is a high natural frequency of cytochrome B mutants which leads to a high failure rate if atovaquone is used on its own to treat malaria. Specific mutations (Y268S, Y268C) have been shown to confer resistance in vivo,^[4]^[5]^[6] but there are other mechanisms of resistance that remain unknown.^[7]

References

↑ (ATN) Atovaquone (Mepron; 566C80) Approved for Pneumocystis; Drug Development, Activism Success
↑ Mepron
↑ Malarone: New Malaria Medication With Fewer Side-effects
↑ Färnet A, Lindberg J, Gil P; et al. (2003). "Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguoanil hydrochloride: case reports". Brit Med J. 326: 628&ndash, 29.
↑ Fivelman QL, Butcher GA, Adagu IS; et al. (2002). "Malarone treatment failure and in-vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria". Malaria J. 1: 1.
↑ Schwartz E, Bujanover S, Kain KC (2003). "Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveller to east Africa". Clin Infect Dis. 37: 450&ndash, 51.
↑ Wichmann O, Muehlen M, Gruss H; et al. (2004). "Malarone treatment failure not associated with previously described mutations in the cytochrome b gene". Malaria J. 3: 14.

External links

Template:Agents against amoebiasis and other protozoal diseases

Template:SIB

de:Atovaquon

Template:WikiDoc Sources

[1] (ATN) Atovaquone (Mepron; 566C80) Approved for Pneumocystis; Drug Development, Activism Success

[2] Mepron

[3] Malarone: New Malaria Medication With Fewer Side-effects

[4] Färnet A, Lindberg J, Gil P; et al. (2003). "Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguoanil hydrochloride: case reports". Brit Med J. 326: 628&ndash, 29.

[5] Fivelman QL, Butcher GA, Adagu IS; et al. (2002). "Malarone treatment failure and in-vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria". Malaria J. 1: 1.

[6] Schwartz E, Bujanover S, Kain KC (2003). "Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveller to east Africa". Clin Infect Dis. 37: 450&ndash, 51.

[7] Wichmann O, Muehlen M, Gruss H; et al. (2004). "Malarone treatment failure not associated with previously described mutations in the cytochrome b gene". Malaria J. 3: 14.

[1]

[2]

[3]

[4]

[5]

[6]

[7]